Latest Insider Transactions at An2 Therapeutics, Inc. (ANTX)
This section provides a real-time view of insider transactions for An2 Therapeutics, Inc. (ANTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AN2 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AN2 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
Eric Easom Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,907
+50.0%
|
-
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Open market or private purchase
|
Indirect |
166,666
+7.01%
|
$2,499,990
$15.0 P/Share
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,430,714
+33.05%
|
-
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
153,334
+14.49%
|
$2,300,010
$15.0 P/Share
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Conversion of derivative security
|
Indirect |
751,621
+32.53%
|
-
|
|
Mar 29
2022
|
Joseph S Zakrzewski |
BUY
Conversion of derivative security
|
Direct |
98,199
+50.0%
|
-
|
|
Mar 29
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+27.03%
|
$24,999,990
$15.0 P/Share
|
|
Mar 29
2022
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,999,997
+50.0%
|
-
|